US equities |
MU $916.56 ▼-3.84% NVDA $221.05 ▼-3.27% AAPL $342.40 ▲+0.33% AMD $570.45 ▼-5.79% META $737.30 ▼-3.30% TSLA $366.66 ▼-2.28% SNDK $1,403.76 ▼-5.30% SPCX $152.18 ▼-2.79%
FinancialContent

Articles published by Scholar Rock, Inc.

News headline image
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock, Inc.
Via Business Wire
Tickers SRRK
News headline image
Scholar Rock to Present at the 2026 Jefferies Global Healthcare Conference
From Scholar Rock, Inc.
Via Business Wire
Tickers SRRK
News headline image
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock, Inc.
Via Business Wire
Tickers SRRK
News headline image
Scholar Rock Highlights 2026 Strategic Priorities
From Scholar Rock, Inc.
Via Business Wire
Tickers SRRK
News headline image
Scholar Rock to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Scholar Rock, Inc.
Via Business Wire
Tickers SRRK
News headline image
Scholar Rock Announces New Preclinical Data for SRK-439 Showing Significant Lean Mass Increase and Enhanced Fat Mass Loss with Metformin
From Scholar Rock, Inc.
Via Business Wire
Tickers SRRK
News headline image
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock, Inc.
Via Business Wire
Tickers SRRK
News headline image
Scholar Rock Provides Corporate Update and Highlights Priorities for 2024
From Scholar Rock, Inc.
Via Business Wire
Tickers SRRK
News headline image
Scholar Rock Reports Third Quarter 2023 Financial Results and Highlights Business Progress
From Scholar Rock, Inc.
Via Business Wire
Tickers SRRK
News headline image
New 36-Month Apitegromab Extension Data Reinforce Long-Term Substantial and Sustained Improvement of Motor Function in Phase 2 TOPAZ Trial Patients with Nonambulatory Spinal Muscular Atrophy
From Scholar Rock, Inc.
Via Business Wire
Tickers SRRK
News headline image
Scholar Rock Reports First Quarter 2023 Financial Results and Highlights Business Progress
From Scholar Rock, Inc.
Via Business Wire
Tickers SRRK
News headline image
Scholar Rock Announces Issuance of U.S. Patent Broadly Relevant to Inhibitors of Myostatin Activation
From Scholar Rock, Inc.
Via Business Wire
Tickers SRRK
News headline image
Scholar Rock Presents Biomarker Strategy to Support the SRK-181 DRAGON Phase 1 Proof-of-Concept Trial at the American Association for Cancer Research Annual Meeting
From Scholar Rock, Inc.
Via Business Wire
Tickers SRRK